Rhenman & Partners Asset Management AB Buys 6,500 Shares of IQVIA Holdings Inc. $IQV

Rhenman & Partners Asset Management AB boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 50.0% during the third quarter, Holdings Channel reports. The fund owned 19,500 shares of the medical research company’s stock after acquiring an additional 6,500 shares during the period. Rhenman & Partners Asset Management AB’s holdings in IQVIA were worth $3,704,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA during the 2nd quarter valued at about $515,772,000. Norges Bank purchased a new stake in IQVIA in the second quarter worth approximately $270,160,000. AQR Capital Management LLC grew its position in IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Laurel Wealth Advisors LLC raised its stake in shares of IQVIA by 15,755.2% during the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on IQV shares. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. UBS Group decreased their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Morgan Stanley set a $240.00 target price on IQVIA in a research note on Wednesday, February 11th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Finally, Truist Financial lowered their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $231.13.

IQVIA Stock Down 2.2%

IQV stock opened at $174.56 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a market capitalization of $29.62 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39. The business’s 50 day moving average price is $207.22 and its two-hundred day moving average price is $207.47. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.